ArticleDiscover oncology2026
Characterization of telomere-related gene subtypes in lung adenocarcinoma and their implications for prognosis and treatment.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTelomeres, located at chromosome ends, regulate cell division and maintain genomic stability. Telomere-related genes (TRGs) play essential roles in tumorigenesis and immune escape, but their mechanisms in lung adenocarcinoma (LUAD) are not fully understood.
methodsThis study integrated genomics, transcriptomics and pathological images to analyze TRGs expression in LUAD. Univariate Cox regression identified 278 TRGs linked to prognosis. Using consensus clustering, 1086 LUAD patients were classified into two distinct molecular subtypes (Cluster 1 and Cluster 2). Reliability was validated through non-negative matrix factorization (NMF) and nearest template prediction (NTP), and deep learning models (CLAM, TransMIL, CAMIL) were constructed to predict these molecular subtypes from whole-slide images (WSIs).
resultsOur study found that TRG activation is associated with the occurrence, progression, and poor prognosis of LUAD. TRG expression-based stratification identified subtypes with distinct clinical outcomes. Specifically, Cluster 1 showed a higher frequency of KRAS mutations, together with high microsatellite instability (MSI), increased immune infiltration, and activation of the immune cycle, along with a better response to immune checkpoint blockade (ICB) therapy and more favorable patient prognosis. In contrast, Cluster 2 was characterized by high tumor mutational burden (TMB) and homologous recombination deficiency (HRD). Although these genomic features would be expected to enhance tumor immunogenicity, Cluster 2 exhibited profound adaptive immune resistance, including marked T-cell exhaustion (elevated LAG3 and TIGIT) and a profoundly immunosuppressive tumor microenvironment (TME). Microbial profiling further revealed that the genera Blautia, Faecalibacterium, and Leuconostoc were significantly enriched in Cluster 1. Finally, we developed a deep learning model that accurately predicts TRG-based subtypes, providing preliminary support for the potential clinical utility of this classification framework.
conclusionThis study clarifies the association between TRGs expression and the biological characteristics of LUAD, highlighting their potential clinical significance in molecular typing and therapeutic guidance, and laying a foundation for personalized diagnosis and treatment strategies for LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.